The Recent Rescheduling of Marijuana:What It Means for America and the Workplace

The federal government has taken one of the most significant steps in decades toward changing how marijuana is classified under U.S. law. In April 2026, the Department of Justice (DOJ) and the Drug Enforcement Administration (DEA) announced that certain marijuana products would be moved from Schedule I to Schedule III under the Controlled Substances Act. This decision marks a historic shift in federal drug policy and has sparked national discussion among lawmakers, healthcare professionals, employers, and the cannabis industry.

For more than 50 years, marijuana had been classified as a Schedule I substance, placing it in the same category as heroin and LSD. Schedule I drugs are considered to have a high potential for abuse and no accepted medical use under federal law. Critics argued that marijuana’s medical benefits and widespread state legalization efforts no longer matched the federal government’s position.

Under the recent change, FDA-approved marijuana products and marijuana distributed through qualifying state medical marijuana programs are now classified as Schedule III substances. Schedule III drugs include medications such as ketamine and Tylenol with codeine, which are recognized as having medical value but still remain regulated. Recreational marijuana, however, remains illegal at the federal level in many situations.

Supporters of the rescheduling believe the move will improve scientific research and patient access to medical treatments. Researchers have long argued that Schedule I restrictions made it difficult to study marijuana’s potential medical benefits. By moving certain cannabis products to Schedule III, universities and healthcare organizations may now face fewer barriers when conducting research.

The change could also have a major financial impact on the cannabis industry. Businesses handling state-approved medical marijuana may now qualify for tax deductions previously unavailable under federal law. Many industry leaders view the change as a step toward broader federal reform in the future.

How Does This Affect a Drug-Free Workplace Policy?

One of the biggest questions employers have asked since the rescheduling announcement is whether current drug-free workplace policies must change. In most cases, the answer is no. Employers still maintain the right to enforce workplace drug policies designed to protect employee safety, productivity, and compliance with federal regulations.

Even with marijuana’s reclassification for certain medical uses, employees are not automatically permitted to use or be impaired by marijuana while working. Employers may still prohibit marijuana use during work hours, restrict employees from reporting to work under the influence, and continue drug testing programs, especially in safety-sensitive industries such as transportation, manufacturing, construction, healthcare, and public safety.

Federal contractors and employers regulated by the U.S. Department of Transportation must still comply with federal drug-free workplace requirements. The Drug-Free Workplace Act remains in effect, and DOT-regulated positions continue to prohibit marijuana use regardless of state laws or medical marijuana authorization.

However, the rescheduling may encourage employers to review and update existing policies to ensure they clearly address marijuana use, medical accommodations, prescription medications, and workplace impairment. Policies should distinguish between lawful off-duty conduct and on-the-job impairment while remaining compliant with both federal and state laws.

Employers may also need to provide additional training for supervisors and employees. Educating staff on impairment recognition, workplace expectations, and the company’s drug-free policy can help prevent confusion as marijuana laws continue to evolve.

Employees should understand that legalization or rescheduling does not eliminate workplace safety responsibilities. Being impaired on the job can still create serious risks for coworkers, customers, and the public. Maintaining a safe, productive, and drug-free workplace remains a priority for organizations across the country.

The recent rescheduling of marijuana represents a major turning point in federal cannabis policy, but it does not eliminate employer rights or workplace safety standards. As laws continue to change, businesses should stay informed, review policies regularly, and communicate clearly with employees to ensure compliance and safety for everyone in the workplace.

The Drug Enforcement Administration (DEA) will hold a new administrative hearing to discuss the broader rescheduling of marijuana beginning on June 29, 2026.

Working Partners® will keep you informed, connected, and up to date throughout the process. If you have questions don’t hesitate to reach out to us by calling us, 614-337-8200 or by email, info@workingpartners.com